Video

Outcomes of the JAVELIN Bladder 100 Trial

Author(s):

Jeanny B. Aragon-Ching, MD, FACP,Srikala Sridhar, MD, MSc, FRCPC

Jeanny B. Aragon-Ching, MD, FACP, describes the outcomes of the JAVELIN Bladder 100 study that she presented at ESMO 2022.

Related Videos
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
1 expert in this video
1 expert in this video
Guru P. Sonpavde, MD
1 expert in this video
1 expert in this video
Guru P. Sonpavde, MD
Janaki Neela Sharma, MD
1 expert in this video
1 expert in this video
Related Content
Urothelial Carcinoma | Image Credit: © Sebastian Kaulitzki- stock.adobe.com
December 19th 2024

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma

Oncology Unplugged
August 7th 2024

Park and Grivas Expand on Treatment Updates in Bladder Cancer

Urothelial Cancer
November 16th 2024

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment

Oncology Unplugged
July 24th 2024

Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer

Gautier Marcq, MD
November 7th 2024

Padeliporfin VTP Maintains Robust Responses and is Safe in Low-Grade Upper-Tract Urothelial Cancer

Janaki Neela Sharma, MD, on urothelial cancer
November 7th 2024

Enfortumab Vedotin Plus Pembrolizumab Leads to Shifts in Frontline Metastatic Urothelial Cancer Management